Adaptive pathways: Why are we cautious? par mcwebmaster | Juin 30, 2016 Adaptive pathways: Why are we cautious? 30.06.2016 In order to improve access to medicines, the European Medicines Agency (EMA) has recently been merrily pushing towards speeding up marketing authorisation for new medicines. Several projects have been launched: GetReal, ADAPTSMART